Published research summaries and educational context for GLP-1 receptor agonists including semaglutide, tirzepatide, and related compounds.
Amycretin, Novo Nordisk’s dual GLP-1/amylin agonist, posted real Phase 2 weight-loss numbers in both injectable and oral form and is now advancing to Phase 3 for obesity. Here’s how it compares to retatrutide and CagriSema.
SURMOUNT-5 put tirzepatide and semaglutide in the same trial, head to head. The result: 20.2% vs 13.7% average weight loss. Here’s what that gap actually means.
The FDA expanded Rybelsus’s approval in October 2025 to include cardiovascular risk reduction for adults with type 2 diabetes, closing the gap between oral and injectable semaglutide’s proven benefits.
Novo Nordisk filed CagriSema with the FDA in December 2025, backed by REDEFINE trial data showing 22.7% average weight loss. Here’s how the semaglutide-plus-amylin combination actually works.
The FDA approved the Wegovy pill — oral semaglutide 25mg — on December 22, 2025, delivering 16.6% average weight loss in the OASIS 4 trial. Here’s how it differs from Rybelsus and Lilly’s rival Foundayo.
Research overview of GLP-1 receptor agonists: the GLP-1 mechanism, approved drugs and their clinical trial data (STEP, SELECT, SURMOUNT), and the investigational pipeline.
GLP-1 receptor agonists are being studied in female reproductive health contexts — including PCOS, ovarian function, and fertility outcomes. Here is what published research reports.
Emerging research has examined GLP-1 receptor expression in reproductive tissue. This covers what published studies report about GLP-1 signaling and male reproductive biology.
